MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:44Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Lipid-lowering agents]]
			[[Category:Omega-3 fatty acids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #244

2026-05-23T04:19:17Z

parser-claude batch MedTemplate pre-fill, Top 300 #244

New page

{{MedTemplate
| generic = Icosapent ethyl (eicosapentaenoic acid ethyl ester, EPA-EE)
| brand = Vascepa
| structure =
| classes = [[:Category:Lipid-lowering_agents|Lipid-lowering agent]], [[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]]
| uses = <vote slug="cv-risk-reduction-statin-residual-use">Cardiovascular risk reduction in patients with elevated triglycerides on statin therapy (REDUCE-IT)</vote>, <vote slug="severe-hypertriglyceridemia-use">Severe hypertriglyceridemia (≥500 mg/dL)</vote>
| starting_dose = 2 g PO BID with meals (4 g/d total)
| preparations = 0.5 g, 1 g capsules
| fda_max = 4 g/d
| pill_id =
| routes = Oral
| onset = Triglyceride lowering at 4-8 weeks; CV benefit emerges over months
| duration = 12 hours
| halflife = ~89 hours (EPA, the active metabolite)<ref name="vascepa-label">FDA Prescribing Information, Vascepa (icosapent ethyl), Amarin, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf</ref>
| bioavailability = Substantially improved with high-fat meal; take with food<ref name="vascepa-label" />
| pregnancy = Limited data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="icosapent-ethyl-mech-claim">Icosapent ethyl is a highly purified ethyl ester of EPA (eicosapentaenoic acid, 20:5 n-3); EPA reduces hepatic VLDL-triglyceride synthesis, raises lipoprotein lipase activity, and has pleiotropic anti-inflammatory, antiplatelet, and membrane-stabilizing effects whose contributions to the REDUCE-IT cardiovascular benefit remain debated.</vote> Unlike combined EPA+DHA preparations (Lovaza), pure EPA does not raise LDL — the structural basis for FDA approval after REDUCE-IT showed a 25% relative risk reduction in CV events over statin therapy alone in high-risk patients. Atrial fibrillation signal is the principal new safety concern emerging from the trial<ref name="vascepa-label" />.
}}

== References ==
<references />

Icosapent Ethyl - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #244